Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome

This study identified PlGF as a significant contributor to the exacerbation of HPS associated with cirrhosis, through its regulation of pulmonary nitric oxide production. Our findings demonstrated that PlGF deficiency mitigates the severity of both cirrhosis and HPS in the CBDL model, highlighting its potential as a therapeutic target in cirrhosis-induced HPS. Notably, this protective effect was absent in the PPVL model, which induces HPS associated with portal hypertension without cirrhosis. These results open avenues for novel pharmacological interventions aiming to improve outcomes for patients with cirrhosis-induced HPS.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2024-12-11
DOI
https://doi.org/10.1016/j.jhepr.2024.101297
Citations
3
Primary Topic
Pregnancy and preeclampsia studies
Type
article
Field-Weighted Citation Impact
1.75

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome

Mina Ottaviani, Emmanuel M. Gonzales, Mina Ha, Frédéric Di Fiore et al.
3 citations
JHEP Reports
Pregnancy and preeclampsia studies
1.75
article

Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome

Mina Ottaviani, Emmanuel M. Gonzales, Mina Ha, Frédéric Di Fiore, F. Robert, Florent Dumont, Christophe Guignabert, Frederic Guinut, Ly Tu, Audrey Coilly, Laurent Savale, Raphaël Thuillet, Marc Humbert, Céline Verstuyft, Olivier Sitbon, Alessandra Cuomo, Corinne Normand, Feriel Benchenouf, Maxime Surbier
article en
3 citations

Abstract

This study identified PlGF as a significant contributor to the exacerbation of HPS associated with cirrhosis, through its regulation of pulmonary nitric oxide production. Our findings demonstrated that PlGF deficiency mitigates the severity of both cirrhosis and HPS in the CBDL model, highlighting its potential as a therapeutic target in cirrhosis-induced HPS. Notably, this protective effect was absent in the PPVL model, which induces HPS associated with portal hypertension without cirrhosis. These results open avenues for novel pharmacological interventions aiming to improve outcomes for patients with cirrhosis-induced HPS.

JHEP ReportsVol. 7(3)
Centre National de la Recherche Scientifique (FR), Inserm (FR), Aix-Marseille Université (FR), Université Paris-Saclay (FR), Janssen (France) (FR), Assistance Publique – Hôpitaux de Paris (FR), Hypertension pulmonaire : physiopathologie et innovation thérapeutique (FR), Federico II University Hospital (IT), Centre d’Immunologie de Marseille-Luminy (FR), Bicêtre Hospital (FR), Hôpital Paul-Brousse (FR), Centre d'Immunophénomique
Fondation du Souffle, Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale, Chancellerie des Universités de Paris
Zero hunger
Openalex Percentile: Top 14%
Pregnancy and preeclampsia studies
1.75
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.